Study patients and data collection
This study consists of 510 patients who were prescribed by Seoul
National University Hospital with edoxaban between March 1, 2016 and
June 30, 2017. Patients who were 18 or older and received proper dosage
of edoxaban based on Lixiana package insert (Korean version) [12]
were eligible for the study. Patients who received inappropriate dose of
edoxaban were excluded. Data collection was conducted using electronic
medical records. Data on age, sex, weight, serum creatinine,
comorbidities, concurrent medication, international normalized ratio
(INR) measurements, history of bleeding complications, and liver
function test (cirrhosis or bilirubin >2x normal, or
aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase
>3x normal) were collected. Bleeding complications were
classified as major, clinically relevant non-major, or minor bleeding
using the scheme detailed in the International Society on Thrombosis and
Hemostasis criteria [13].
This study was approved by the Institutional Review Board of the Seoul
National University Hospital (approval number: H-1809-044-971).